Low-density lipoprotein-cholesterol (LDL-C) is a well-accepted causal risk factor for athero-
thrombotic cardiovascular disease, as demonstrated in large epidemiological studies,
including Mendelian randomization data. Several randomized controlled trials and meta-
analyzes have shown that lipid lowering therapies, such as statins and more recently the
non-statin agents ezetimibe and Proprotein Convertase Subtilisin Kexin type 9 (PCSK9)
monoclonal antibodies (mAb), reduce cardiovascular events across a broad range of …